



9 February 2010

Immunodiagnostic Systems Holdings PLC

Immunodiagnostic Systems Holdings PLC ("the Company"), a leading producer of diagnostic testing kits, announces that on 8 February 2010, 66,723 ordinary shares of 2p each in the Company (the "Ordinary Shares") were allotted in a board meeting to satisfy an exercise of options.

Additionally, at the same board meeting 2,495 Ordinary Shares were allotted to satisfy options exercised under a SAYE scheme. In aggregate 69,218 Ordinary Shares have been allotted and application will be made at the earliest practicable opportunity for admission of the new ordinary shares to trading on AIM.

Total Voting Rights

In accordance with FSA's Disclosure and Transparency Rules, the Company advises that its increased issued share capital comprises 27,852,783 Ordinary Shares. The voting rights of all of these shares are identical with each share carrying the right to one vote. The Company holds no ordinary shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Immunodiagnostic Systems Holdings PLC under the Disclosure and Transparency Rules.

Contacts:

Immunodiagnostic Systems Holdings PLC
Roger Duggan, CEO
Paul Hailes, Finance Director

Tel: 0191 519 0660

Brewin Dolphin Investment Banking
Andrew Emmott
Sean Wyndham-Quin

Tel: 0845 213 4730

Walbrook PR Ltd
Ben Knowles

Tel: 020 7933 8788
Mob: 07900 346 978